Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous Treatment
Completed · Phase 2
Conditions studied: Leukemia, Lymphoma, Lymphoproliferative Disorder
In brief
RATIONALE: Everolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer. PURPOSE: This phase II trial is studying the side effects and how well everolimus works in treating patients with lymphoma that has relapsed or not responded to previous treatment.
Key facts
- Study ID
- NCT00436618
- Run by
- Mayo Clinic
- People needed
- 277
- Starts
- 2005-08-01
- Expected to finish
- 2019-10-09
- Last updated by the study team
- 2019-10-22
Who can join
Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Mayo Clinic Scottsdale — Scottsdale, Arizona, United States
- Mayo Clinic - Jacksonville — Jacksonville, Florida, United States
- Mayo Clinic Cancer Center — Rochester, Minnesota, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.